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Background: Blockade of granulocyte macrophage colony-stimulating factor (GM-CSF) and its receptor (GM-CSFRα)
is being successfully tested in trials in rheumatoid arthritis (RA) with clinical results equivalent to those found with
neutralization of the current therapeutic targets, TNF and IL-6. To explore further the role of GM-CSF as a pro-
inflammatory cytokine, we examined the effect of anti-GM-CSFRα neutralization on myeloid cell populations in
antigen-driven arthritis and inflammation models and also compared its effect with that of anti-TNF and anti-IL-6.
Methods: Cell population changes upon neutralization by monoclonal antibodies (mAbs) in the antigen-induced
arthritis (AIA) and antigen-induced peritonitis (AIP) models were monitored by flow cytometry and microarray.
Adoptive transfer of monocytes into the AIP cavity was used to assess the GM-CSF dependence of the development of
macrophages and monocyte-derived dendritic cells (Mo-DCs) at a site of inflammation.
Results: Therapeutic administration of a neutralizing anti-GM-CSF mAb, but not of an anti-colony-stimulating
factor (anti-CSF)-1 or an anti-CSF-1R mAb, ameliorated AIA disease. Using the anti-GM-CSFRα mAb, the relative
surface expression of different inflammatory myeloid populations was found to be similar in the inflamed tissues
in both the AIA and AIP models; however, the GM-CSFRα mAb, but not neutralizing anti-TNF and anti-IL-6 mAbs,
preferentially depleted Mo-DCs from these sites. In addition, we were able to show that locally acting GM-CSF
upregulated macrophage/Mo-DC numbers via GM-CSFR signalling in donor monocytes.
Conclusions: Our findings suggest that GM-CSF blockade modulates inflammatory responses differently to TNF
and IL-6 blockade and may provide additional insight into how targeting the GM-CSF/GM-CSFRα system is
providing efficacy in RA.
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Clinical trials assessing blockade of granulocyte macro-
phage colony-stimulating factor (GM-CSF) or its recep-
tor (GM-CSFRα) have commenced in rheumatoid
arthritis (RA), psoriasis, multiple sclerosis and asthma,
with some encouraging RA data [1, 2]. Questions, such
as which is the key cell type(s) regulated by GM-CSF
and whether it has pro-survival, differentiation and/or
activation functions, remain to be addressed. For
example, there is debate as to whether during an in-
flammatory response differentiation of inflammatory,
monocyte-derived dendritic cells (Mo-DCs) is GM-CSF-
dependent [3–9]. Given that anti-TNF and anti-IL-6 ther-
apies have been successful in RA and that head-to-head
trials between anti-GM-CSFRα and anti-TNF are ongoing
[2], it would be useful to know how similar or not the
biology of the pro-inflammatory activity of GM-CSF is to
the respective biology of these other cytokines.
The basic unit structure of the dodecameric GM-CSF
receptor (GM-CSFR) consists of a binding, cytokine-
specific α subunit and a signaling β subunit [10]. It has
been reported that there is a significant increase in the
number of GM-CSFR α-subunit (GM-CSFRα) positive
synovial macrophages in the RA synovium and that
GM-CSFRα neutralization suppresses disease activity in
the murine collagen-induced arthritis model [11]. It
would seem that a GM-CSFRα monoclonal antibody
(mAb) may be a useful tool to define GM-CSFRα ex-
pression on GM-CSF-responsive cells driving an inflam-
matory response and to be able to compare the efficacy
with an anti-ligand therapeutic strategy.
The murine monoarticular antigen-induced arthritis
(AIA) model is a widely used inflammatory arthritis
model and is characterized by infiltration of neutrophils
and mononuclear cells, synovitis (pannus formation) and
erosion of cartilage and bone, thus replicating several
features similar to those in RA [12–17]. An advantage of
the AIA model lies in the exactly defined initiation of
the arthritis, elicited by antigen injection into the knee
joint cavity [18]. Using either gene-deficient mice or
antibody neutralization strategies it has been found that
both TNF and IL-6 contribute to at least some extent to
AIA progression [19–24]. As we have identified suppres-
sion of AIA disease and pain in GM-CSF-/- mice [25],
this particular model may be useful for comparing the
effects of its blockade on myeloid cell populations with
that of TNF or IL-6.
The sterile peritoneal cavity is a convenient location to
induce inflammation, to analyse inflammatory cell popu-
lations and to study the evolution of the inflammatory
response on account of the easy access to the peritoneal
exudate. We developed the antigen-induced peritonitis
(AIP) model [26] because it has elements of both innate
and acquired immunity and it follows a similar primingand challenge protocol with the same antigen as the
AIA model. We therefore reasoned that it may represent
a convenient surrogate model for this particular arthritis
model in which to study changes in cell populations. We
have shown that it also demonstrates GM-CSF depend-
ence [27] and have begun to explore the mode of action
of GM-CSF as a pro-inflammatory cytokine using this
model [28].
We report here that GM-CSFRα blockade leads to
myeloid population changes in AIA and AIP, which dif-
fer to those observed with TNF or IL-6 blockade. Add-
itionally, we show that an anti-GM-CSFRα mAb can be
used to directly monitor surface GM-CSFRα expression
by flow cytometry and that its administration can lead to
similar effects on myeloid cell populations as ligand
neutralization at a site of inflammation, including prefer-
ential reduction in Mo-DCs.Methods
Mice
C57BL/6 mice (both CD45.1 and CD45.2) were obtained
from WEHI, Kew (Victoria, Australia). Csf1r-EGFP
(MacGreen) mice [29], backcrossed onto the C57BL/6
background, are bred in our on-site animal facility at the
University of Melbourne. Mice deficient in both βc and
βIL-3 [30], referred to here as Csf2rb
-/-Csf2rb2-/- mice,
backcrossed onto the C57BL/6 background, were supplied
by A. Lopez (Hanson Institute, Adelaide, Australia). Mice
were fed standard rodent chow and water ad libitum.
Mice of both sexes, aged 8–12 weeks, were used; experi-
ments were approved by The University of Melbourne
Animal Ethics Committee.Antigen-induced models
Antigen-induced arthritis (AIA) was induced as previ-
ously described using methylated BSA (mBSA) as anti-
gen [25]. Briefly, mice were immunized with mBSA
(Sigma-Aldrich, St Louis, MO, USA), emulsified in
complete Freund’s adjuvant (CFA), intradermally in the
base of the tail on day -7 and arthritis was induced 7 days
later (day 0) by an intra-articular (i.a.) injection of mBSA
into the right knee, the left knee being injected with
PBS. Histological analysis was performed on the knee
joints, which were scored separately (0–3) for cellular in-
filtration, cartilage damage and bone erosion (H&E
stain), and proteoglycan loss (Safranin O/fast green
stain) [25].
Antigen-induced peritonitis (AIP) was induced as pre-
viously described again using mBSA [28]. Briefly, mice
were immunized intradermally with mBSA, emulsified in
CFA, as described for the AIA model above; 14 days
later, the primary immunization protocol was repeated
as a boost. Seven days later, mice were injected
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tonitis (day 0).
mAb treatment
Mice were treated i.p. with 150 μg anti-GM-CSF
(22E9.11, J. Abrams) [28], 250 μg anti-CSF-1R (ASF98,
S-I Nishikawa) [28], 150 μg anti-CSF-1 (F. Dodeller,
MorphoSys, Munich, Germany) [28, 31], 750 μg anti-GM-
CSFRα (CAM-3003) [11], 750 μg anti-TNF (MP6-XT22,
Biolegend, San Diego, CA, USA), 750 μg anti-IL-6 (Biole-
gend) and their respective isotype control mAb, at the time
points indicated.
Cell isolation and fluorescence-activated cell sorting
(FACS) analysis
Cell suspensions were prepared from the synovium or
peritoneal cavity and analysed by flow cytometry [28, 32,
33]. For synovial cells, mice were perfused with 20 ml
PBS and the patellae from the knee joints were dissected
and the synovium digested (1 mg/ml collagenase type
IV, 0.5 mg/ml neutral protease, 50 μg/ml DNase I in
PBS) for 45 minutes at 37 oC, then passed through a
70-μm nylon mesh to obtain a single cell suspension.
Cells were washed twice in PBS, followed by cell count-
ing using BD Trucount tubes (BD Biosciences). Joint cells
were incubated with Fc block (anti-CD16/32, clone 2.4G2)
and stained using the following antibodies: APC-Cy7-
conjugated CD45 (30-F11), BV421-conjugated CD11b
(M1/70), PE-Cy7-conjugated CD11c (N418), BV510-
conjugated I-A/I-E (M5/114.15.2), FITC-conjugated Gr-1
(RB6-8C5), PE-conjugated F4/80 (BM8) and APC-
conjugated GM-CSFRα (CAM-3003). Note that Gr-1 was
used for staining synovial cells rather than Ly6G and Ly6C
due to the number of available channels.
Peritoneal cells were collected by lavage with 5 ml
cold PBS, followed by washing in PBS and cell counting
using either trypan blue or BD Trucount tubes (BD
Biosciences). Cells were incubated with Fc block (anti-
CD16/32, clone 2.4G2) and stained using the following
antibodies: PE-conjugated CD115 (AFS98), PE-TxRed
or PE-Cy7-conjugated CD11b (M1/70), BV421-
conjugated CD11c (HL3), BV510-conjugated I-A/I-E
(M5/114.15.2), APC-Cy7 conjugated Ly6G (1A8), FITC-
or PE-Cy7-conjugated Ly6C (HK1.4), FITC-conjugated
CD45.1 (A20), FITC-conjugated CD45.2 (104) and
APC-conjugated GM-CSFRα (CAM-3003).
All fluorochrome-conjugated antibodies were sourced
from BD Biosciences, Biolegend, or eBioscience, with the
exception of αGM-CSFRα (CAM-3003) mAb. CAM-3003
was conjugated with APC using a Lightning-Link antibody
labelling kit (Innova Biosciences) according to manu-
facturer’s protocol. Cell viability was determined using
7-AAD (BD Biosciences) and data were acquired on a
CyAn flow cytometer (Beckman Coulter). Compensationwas acquired using single-stained samples and specificity
of antibody staining was determined by the fluorescence-
minus-one method. Analysis was performed using Kaluza
1.2 software (Beckman Coulter).
Adoptive cell transfer
Bone marrow was flushed from the tibias and femurs of
donor mice, red blood cells lysed and CD115+ cells were
either MACS-enriched, using CD115-Biotin antibody
and anti-Biotin microbeads (Miltentyi Biotec), or FACS
sorted. Monocyte purity after enrichment was >90%;
1.0 × 106 enriched monocytes were transferred i.p. into
mBSA-challenged AIP mice on day 2.
Gene expression analysis
Total RNA was isolated (Qiagen) from total peritoneal
exudate cells (PECs), magnetic bead-isolated CD115+
PECs, or sorted CD115+ CD45.1+ donor PECs, from day
4 AIP. Individual gene expression was measured by
RT-PCR using TaqMan Gene Expression Arrays (Ther-
moFisher). For transcriptomic analysis, RNA was
quantified, normalised and verified by Bioanalyzer
(Agilent) prior to processing onto Genechip Mouse
Gene 2.0ST Microarrays (Affymetrix). Sorted CD115+
donor PECs additionally underwent PCR amplification
prior to analysis (Nugen). Normalisation across all arrays
was achieved using the robust multi-array average (RMA)
expression measure [34] which results in expression mea-
sures (summarised intensities) in log base 2. Significant
genes from each comparison were analysed for enrich-
ment of Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway membership using a hypergeometric
test. Pathway enrichment (p < 0.05) was assessed separ-
ately for upregulated and downregulated genes.
Statistical analysis
Data are expressed as mean ± SEM. Statistical differences
were assessed using the unpaired Student’s t test or one-way
analysis of variance (ANOVA). For histologic scores,
Kruskal-Wallis one-way ANOVA was used. P ≤0.05 was
considered statistically significant. In the microarray analysis,
differentially expressed genes were defined as fold change
≥2 with an adjusted p value <0.01. Empirical Bayesian
analysis was applied (including vertical within a given com-
parison) and the p value was adjusted for multiple testing.
Results
GM-CSF, but not CSF-1, neutralization suppresses AIA
We have previously shown, using knockout mice, that
AIA is partially dependent on GM-CSF [25]; however,
this approach cannot delineate whether GM-CSF is act-
ing during the antigen-priming, antigen-challenge (ef-
fector) and/or the more chronic inflammatory phase.
Therefore to explore when GM-CSF might be acting in
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iveness of both prophylactic and therapeutic treatment
with a neutralizing anti-GM-CSF mAb (22E9). Treating
AIA-primed mice prophylactically with anti-GM-CSF
mAb, on days -2 and 0, led to some reduction in cell in-
filtration 3 days after AIA induction (day 0), as judged
by histological analysis (H&E stain) compared to isotype
mAb treatment (Fig. 1a and b). There was also signifi-
cantly less cartilage damage (H&E stain) and proteogly-
can loss (Safranin O/fast green stain) in the former
group (Fig. 1a and b). Treating AIA-primed mice thera-
peutically on days 2 and 4 post AIA induction (day 0)
led to a trend towards a reduction in cell infiltration
and proteoglycan loss at day 7 and a significant reduc-
tion in the degree of cartilage damage and bone erosion
compared to isotype-treated and PBS-treated AIA-
primed mice (Fig. 1c and d). Treating mice with anti-GM-Fig. 1 Granulocyte macrophage colony-stimulating factor (GM-CSF) but n
antigen-induced arthritis (AIA). AIA-primed mice were treated with PBS, a
either prophylactically (days -2 and 0) (a and b) or therapeutically (days 2 and 4
of methylated bovine serum albumin (mBSA). Histological analysis of the arthriti
induction. a, c Representative H&E (left) and Safranin O/fast green (right) stained
Data are expressed as mean + SEM, n = 6–12 mice/group; *p< 0.05, **p< 0.01, *CSF mAb on days 9 and 11 post AIA onset (chronic
phase) had no effect on cell infiltration but did lead to a
significant reduction in bone erosion and a trend towards
a reduction in cartilage damage at day 14 compared to
isotype-treated mice (data not shown). Thus, the earlier
the anti-GM-CSF mAb treatment was started the more
significant was the reduction in cell infiltration, while both
prophylatic and therapeutic anti-GM-CSF mAb treat-
ments resulted in reduced joint damage, i.e., GM-CSF
blockade during either the acute or the more chronic
phase of AIA ameliorated the structural changes.
We also assessed whether CSF-1, which acts more spe-
cifically on populations of the mononuclear phagocyte
system (MPS) via CD115 (c-Fms) [35], is involved in
AIA progression. AIA-primed mice were treated both
prophylactically and therapeutically with an anti-CSF-1
mAb; however, it had no effect on cell infiltration orot colony-stimulating factor (CSF-1) neutralization suppresses
nti-GM-CSF, anti-CSF-1R, anti-CSF-1 or isotype monoclonal antibodies,
) (c and d), with arthritis being induced on day 0 by intra-articular injection
c joints was performed on day 3 (a and b) and day 7 (c and d) post arthritis
sections. b, d Quantification of histological appearances. PG proteoglycan.
**p< 0.001, anti-GM-CSF vs. PBS or IgG2a
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for the CSF-1R [1], we also tested an anti-CSF-1R mAb
and obtained the same negative findings, suggesting that
neither CSF-1 nor IL-34 is critical for AIA progression.GM-CSFRα expression and the effect of its blockade on
myeloid cell populations in AIA
It has been previously shown that in the synovial tissue of
patients with RA there is a significant increase in GM-
CSFRα-expressing cells and that the receptor is expressed
by macrophages [11]. GM-CSFRα neutralization using the
mAb, CAM-3003, was shown to be as effective as anti-
GM-CSF and anti-TNF mAbs in suppressing manifesta-
tions of murine collagen-induced arthritis, including
the degree of synovial inflammation [11, 33, 36, 37]; the
clinical benefit is also similar in RA trials using GM-
CSF receptor or GM-CSF neutralizing mAbs [2, 38].
For these and subsequent experiments we utilized the
GM-CSFRα blocking mAb, CAM-3003, both as a neu-
tralizing antibody in vivo and to detect GM-CSFRα
expression by flow cytometry. This allowed us to study
the expression of the receptor on specific cell popula-
tions at sites of inflammation and to verify that our
experiments were not compromised by a lack of target
coverage in the anti-GM-CSFRα-treated mice, by asses-
sing receptor occupancy simultaneously with the
changes in their respective cell numbers.
Notwithstanding the challenges faced in defining cat-
egorically mononuclear phagocyte system (MPS) popu-
lations [28, 39–42], we first identified the different
synovial myeloid populations, using a similar gating
strategy to the one we previously published for the AIP
model [28], with some notable modifications - the
marker F4/80 was used in place of CD115 (CSF-1R) for
analysis of the synovial macrophage/Mo-DC popula-
tions, as done by Weiss et al. [17], because surface
CD115 could not be detected following tissue digestion
and because we have previously shown that the CD115+
populations in the inflamed AIP peritoneal cavity are also
F4/80+ [28]. The gating strategy is provided in Fig. 2a
using the following markers: CD45+ F4/80-CD11b+ SScint
Gr-1+ neutrophils, CD45+F4/80+CD11b+ MPS popula-
tions (CD11c+MHCII+ Mo-DCs (R1), CD11c-MHCII+
macrophages (R2), CD11c-MHCII- macrophages (R3)),
CD45+F4/80-CD11b+SScloGr-1+/- monocytes, CD45+F4/
80-CD11c+ MHCII+ conventional dendritic cells (cDCs)
and CD45+F4/80intSSchi eosinophils. Anti-Gr-1 mAb
stains both Ly6G and Ly6C. We confirmed that the neu-
trophils were Ly6G+Ly6C+, while the F4/80-CD11b+SSclo
monocytes were Ly6G- and either Ly6C+ or Ly6C-
(Additional file 1A). Furthermore, we showed that
Ly6G+ neutrophils were CD64- and F4/80+ macro-
phages/Mo-DCs were CD64+ (Additional file 1B).Following AIA induction there was an influx of CD45+
cells into the joint, with neutrophils being the predomin-
ant cell type, comprising 50.5 ± 1.6% of CD45+ synovial
cells at day 5. F4/80+ MPS populations (comprising
Mo-DCs (R1) and MHCII+/- macrophages (R2 and R3,
respectively) (Fig. 2a)) made up a further 17.6 ± 2.0% of
CD45+ synovial cells, with monocytes (4.8 ± 0.7%), eo-
sinophils (4.7 ± 0.4%) and cDCs (0.6 ± 0.1%) being
minor populations. Using the CAM-3003 mAb, GM-
CSFRα was highly expressed on each of the F4/80+
MPS populations, monocytes and cDCs (Fig. 2b) and
further enhanced during inflammation, whereas on
neutrophils and eosinophils its levels were low (Fig. 2b)
and barely detectable above that of the isotype control
(data not shown). AIA-primed mice were treated with
the mAbs on days -1 and 2 (with i.a. challenge with
mBSA again at day 0), and synovial cells were analysed
once more on day 5. This prophylactic treatment proto-
col was chosen as it covers the time period when cell
infiltration into the joint is maximal, thus, allowing us
to determine the effect of mAb blockade on the infil-
trating cell populations. CAM-3003 treatment, but not
that with the isotype control, CAT-004, reduced the levels
of detectable GM-CSFRα on the F4/80+ MPS populations,
monocytes and cDCs (Fig. 2b), suggesting that the avail-
ability of free receptor was reduced on these cell types.
The low receptor levels on neutrophils and eosinophils
meant that a similar analysis could not be conducted.
As regards changes in cell population numbers follow-
ing prophylactic CAM-3003 treatment (days -1 and 2),
there were significantly fewer Mo-DCs and eosinophils
(vs. CAT-004 isotype control) in AIA mice at day 5
(Fig. 2c); there was also a trend towards fewer neutro-
phils, CD11c-MHCII- macrophages and cDCs, but not
towards fewer CD11c-MHCII+ macrophages or Gr-1+/-
monocytes. Interestingly, as a proportion of F4/80+ cells,
Mo-DCs were the only cell type to be significantly lower
following CAM-3003 treatment indicating a preferential
reduction (Fig. 2d). Gr-1 expression varied on the differ-
ent F4/80+ subpopulations, with 66.6 ± 4.3% of CD11c-
MHCII- macrophages, 42.4 ± 3.5% CD11c-MHCII+ mac-
rophages and 25.6 ± 3.4% Mo-DCs being Gr-1+ at day 5.
CAM-3003 treatment had no effect on the proportion of
Gr-1+ cells in each MPS population (69.0 ± 3.0% CD11c-
MHCII- macrophages, 45.2 ± 2.8% CD11c-MHCII+ mac-
rophages and 34.7 ± 3.1% Mo-DCs) (data not shown).
TNF and IL-6 have been implicated in AIA pathogen-
esis [19–24], and blocking antibodies against them have
therapeutic effects in RA [43]. We reasoned that mech-
anistic comparisons between GM-CSFRα neutralization
and that of these other pro-inflammatory cytokines may
be informative. We therefore explored whether TNF or
IL-6 blockade led to similar changes in AIA cell popula-
tions as GM-CSFRα blockade. As for the CAM-3003
Fig. 2 (See legend on next page.)
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Fig. 2 Effect of granulocyte macrophage colony-stimulating factor receptor α (GM-CSFRα), TNF and IL-6 blockade on myeloid cell populations in
antigen-induced arthritis (AIA). a Representative FACS plots showing the gating strategy used to identify CD45+ myeloid populations in the AIA
knee joint. F4/80intSSchi eosinophils (Eos), F4/80+CD11c+MHCII+ monocyte-derived dendritic cells (Mo-DCs) (R1), F4/80+CD11c-MHCII+ macrophages
(Macs) (R2), F4/80+CD11c-MHCII- macrophages (R3), F4/80-CD11c+ MHCII+ conventional dendritic cells (cDCs), F4/80-CD11b+SScint Gr-1+ neutrophils
(Neutro) and F4/80-CD11b+SScloGr-1+/- monocytes (Mo). b-d AIA-primed mice were treated with PBS, CAT-004 isotype monoclonal antibody
(mAb) or CAM-3003 mAb on day -1 and day 2. Cells were harvested at day 5 post AIA induction and synovial populations analysed. b GM-CSFRα
expression on myeloid cell populations. c Total CD45+ cells and myeloid cell populations. d MHCII- macrophages, MHCII+ macrophages and
Mo-DCs as a percentage of F4/80+ cells. e-f AIA-primed mice were treated with anti-TNF mAb, anti-IL-6 mAb or IgG1 isotype mAb on day -1
and day 2. Cells were harvested at day 5 post AIA induction and synovial populations analysed. e Total cells and myeloid cell populations.
f Number of Gr-1+ and Gr-1- cells in the different F4/80+ mononuclear phagocyte system (MPS) cell populations. Data are expressed as mean
± SEM; n = 10–16 mice/group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, CAT-004 vs. CAM-3003, or anti-TNF or anti-IL-6 vs. IgG1
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before (day -1) and after (day 2) i.a. antigen challenge
with anti-TNF or anti-IL-6 mAbs and their isotype con-
trol, with mice being killed at day 5. There was a trend
for fewer total cells and neutrophils (vs. IgG1 isotype
control) in both anti-TNF-treated and anti-IL-6 treated
AIA mice, being statistically significant for the latter cell
type for anti-TNF mAb treatment (Fig. 2e), thus con-
firming previous findings [24, 44]. However, unlike
CAM-3003-treated mice (Fig. 2c), no such significant
decreases in cell numbers were noted for Mo-DCs or
eosinophils following anti-TNF or anti-IL-6 mAb treat-
ment (Fig. 2e).
There were also fewer synovial Gr-1+ monocytes fol-
lowing anti-TNF mAb (Fig. 2e). In line with this, fol-
lowing anti-TNF treatment, significantly fewer Mo-DCs
were Gr-1+ and there was a trend towards fewer
MHCII- and MHCII+ macrophages being Gr-1+
(Fig. 2f ). The reduction in synovial Ly6C+ monocyte
number also occurred in anti-IL-6-treated mice
(Fig. 2e); however, this treatment did not affect the
numbers of Gr-1+ F4/80+ MPS populations (Fig. 2f).
There were no differences in the numbers of Gr-1- MPS
cells between any of the treatment groups (Fig. 2e and f).
Thus, in AIA GM-CSFRα was most highly expressed
on MPS cells and cDCs in the synovium; also adminis-
tration of a neutralizing GM-CSFRα mAb variably
reduced the synovial myeloid populations with a dis-
proportionate effect on Mo-DCs amongst MPS popu-
lations. TNF and IL-6 neutralization had no significant
effect on the numbers of synovial Mo-DCs and eosino-
phils, but reduced the numbers of synovial Gr-1+
monocytes.GM-CSFRα expression and the effect of its prophylactic
blockade in AIP
To characterize the effect of GM-CSFRα blockade on
myeloid cells in greater detail we utilized our AIP model
[28]. It should be noted that the protocol for induction
of AIP is quite similar to AIA, except for the site of anti-
gen (mBSA) challenge [25–28].PEC populations were again analysed by flow cytome-
try. We again used CD115 [28, 32], when analysing
PECs, given its specificity for macrophage-lineage cells
amongst haemopoietic populations. The gating strategy
was as before [28] (Additional file 2) using the following
markers: Ly6G+ neutrophils, Ly6G-CD115+ monocytes/
macrophages/Mo-DCs (CD11c+MHCII+ Mo-DCs (R1),
CD11c-MHCII+ macrophages (R2), CD11c-MHCII-
monocytes (R3)), CD115-Ly6G-CD11c+MHCII+ cDCs
and CD115-Ly6G-CD11bintSSchi eosinophils. Note that,
as previously [28], the CD115+CD11c-MHCII- cells (R3)
in the inflamed peritoneal cavity are referred to as
monocytes, based on their morphology and their being
predominantly Ly6C+.
Following AIP induction, in PBS-treated mice at day 4
(the peak of the cellular response [26, 28]) there was an
influx of cells with 15.8 ± 2.8% of exudate cells being
neutrophils, 47.6 ± 1.9% CD115+ cells (monocytes, mac-
rophages, Mo-DCs), 6.7 ± 0.6% eosinophils and 2.6 ±
0.2% cDCs. As for the synovial cells in the AIA model,
the CAM-3003 mAb was able to detect GM-CSFRα on
the MPS cells (CD115+) and on cDCs (Fig. 3a), whereas
again detection on neutrophils and eosinophils was diffi-
cult (low mean fluorescence intensity (MFI)) (Fig. 3a)
and was barely above that of the isotype control (data
not shown). Similar to what was shown for the AIA
model (Fig. 2b), in the AIP model CAM-3003 treatment
at day -1, but not that with CAT-004, reduced the levels
of detectable GM-CSFRα on the CD115+ cells and cDCs
(Fig. 3a).
Upon prophylactic CAM-3003 administration (day -1),
at day 4 there were also significantly fewer total PECs,
CD11c-MHCII- monocytes, CD11c-MHCII+ macro-
phages, Mo-DCs, neutrophils, eosinophils and cDCs
with 30 mg/kg CAM3003 given i.p. (Fig. 3b), a dose
found to be maximal - interestingly, the effect in general
on cell population numbers was more pronounced than
in the AIA model with data for the CD11c-MHCII+ peri-
toneal macrophages differing from the lack of effect of
CAM-3003 shown above for the CD11c-MHCII+ syn-
ovial macrophages (Fig. 2c). As a proportion of CD115+
cells, only the Mo-DCs were reduced following CAM-
Fig. 3 (See legend on next page.)
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Fig. 3 Effect of granulocyte macrophage colony-stimulating factor receptor α (GM-CSFRα), TNF and IL-6 blockade on myeloid cell populations in
antigen-induced peritonitis (AIP). a-c AIP-primed mice were treated with PBS, CAT-004 isotype monoclonal antibody (mAb) or CAM-3003 mAb on
day -1. Cells were harvested at day 4 post AIP induction and peritoneal exudate cell (PEC) populations analysed. a GM-CSFRα expression on
myeloid cell populations. b Total cells and myeloid cell populations. c MHCII- monocytes/macrophages, MHCII+ macrophages and monocyte-derived
dendritic cells (Mo-DCs) as a percentage of CD115+ cells. d AIP-primed mice were treated with anti-TNF mAb, anti-IL-6 mAb or IgG1 isotype mAb on
day -1 and day 2. Cells were harvested at day 4 post AIP induction and PEC populations analysed. Total cells and myeloid cell populations are shown.
Data are expressed as mean ± SEM; n = 8 mice/group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 for CAT-004 vs. CAM-3003. cDCs conventional
dendritic cells
Cook et al. Arthritis Research & Therapy  (2016) 18:287 Page 9 of 153003 treatment once again indicating their preferential
reduction (Fig. 3c), similar to that previously reported
for the AIP model following blockade of GM-CSF [28]
and to the data above for the AIA model (Fig. 2d).
CAM-3003 treatment had no effect on the proportion of
Ly6C+ cells within each CD115+ subpopulation (data not
shown). Interestingly, the proportion of MHCII+ macro-
phages and Mo-DCs in AIP which were Ly6C+ was sig-
nificantly lower than in AIA (MHCII+ macrophages:
21.7 ± 2.3% vs. 38.6 ± 3.1%, Mo-DCs 4.0 ± 0.4% vs. 24.4 ±
1.5%, AIP vs. AIA).
We next explored whether or not TNF or IL-6 block-
ade led to similar changes in AIP cell populations as
GM-CSFRα blockade using a similar administration
protocol. Mice undergoing AIP were treated before (day
-1) i.p. antigen challenge, i.e., prophylactically, with anti-
TNF, anti-IL-6 mAbs or their isotype control, with mice
killed at day 4; exudate cell populations were again ana-
lysed by flow cytometry. Unlike anti-GM-CSFRα (Fig. 3a),
neither anti-TNF nor anti-IL-6 treatment had significant
effects on myeloid population numbers (Fig. 3d), nor on
detectable GM-CSFRα levels (data not shown), although
there was a trend for fewer MHCII- monocytes/macro-
phages in anti-TNF-treated mice (Fig. 3d).
Thus, as in AIA, GM-CSFRα in AIP can be detected
on certain myeloid populations and anti-GM-CSFRα ad-
ministration led to a preferential reduction of Mo-DCs,
indicating again the convenience of the AIP model in
understanding the role of GM-CSF in inflammation.
TNF and IL-6 neutralization had no significant effect on
the numbers of different PEC populations compared to
GM-CSFRα neutralization.
Gene expression in PECs following GM-CSFRα blockade in
the AIP model
We repeated the above experiment with CAM-3003 and
performed microarray analysis on purified CD115+ peri-
toneal cells (day 4) from the AIP cavity. As the majority
of these cells would have derived from circulating mono-
cytes [28], we first compared their gene expression to
monocytes. Over 2000 genes were significantly different
between these two populations (>2 fold change in ex-
pression and adjusted p value <0.01). However, only 12
genes were significantly changed between isotype-treatedand CAM-3003 treated mice with this particular degree
of stringency (Additional file 3). Although no genes were
changed between isotype- and PBS-treated AIP mice, an
additional 36 genes were found to be differentially
expressed between the PBS and CAM-3003 groups
(Additional file 3). Consequently, we performed pathway
analysis on all the genes that differed between CAM-
3003-treated mice and the PBS-treated or isotype-
treated mice. Using KEGG pathway enrichment analysis,
the only pathways that were significantly changed were
driven by one or two genes. Therefore GM-CSFRα
blockade can by and large reduce the number of infiltrat-
ing myeloid cell populations, but had, at least at the day 4
time point in this model, a surprisingly minor impact on
the CD115+ cell transcriptome (see “Discussion”).
Therapeutic blockade with anti-GM-CSFRα mAb in the AIP
model
In order to gain insight as to when GM-CSF signalling is
required during an inflammatory reaction we next ex-
plored whether in the AIP model a therapeutic delivery
(at day 2) of CAM-3003 after antigen challenge was ef-
fective and, if so, was it in anyway more effective if an
additional prophylactic delivery (at day -1) was given,
the latter protocol being similar to that employed above
in the AIA model (Fig. 2). It can be seen that at day 4
the reductions in total PEC numbers and those of the
various myeloid populations upon therapeutic treatment
with CAM-3003 were similar to those noted if a pre-
treatment was incorporated in the protocol (Fig. 4),
although a single treatment at day 2 did not lead to a
significant reduction in neutrophils, in keeping with
them being the predominant cell type early in an inflam-
matory response. Once again, detectable surface GM-
CSFRα levels were significantly lower on CD115+ cells
and cDCs following both CAM-3003 treatment proto-
cols (data not shown).
Anti-GM-CSFRα mAb suppresses development of Mo-DCs
from donor monocytes in the AIP cavity
The above data in the AIA and AIP models suggests that
GM-CSF signalling is most profoundly controlling the
generation of Mo-DCs from monocyte precursors. To
determine whether this GM-CSF-dependent phenotypic
Fig. 4 Therapeutic blockade with anti-granulocyte macrophage colony-stimulating factor receptor α (anti-GM-CSFRα) monoclonal antibody
(mAb) in antigen-induced peritonitis (AIP). Peritoneal exudate cells (PECs) were harvested from naïve mice or day 4 after AIP induction from mice
treated with CAT-004 (day -1 and day 2), CAM-3003 (day -1 and day 2) and CAM-3003 (day 2) and PEC populations were analysed (FACS). Data are
expressed as mean ± SEM; n = 8 mice/group; *p < 0.05, ***p < 0.001, ****p < 0.0001, vs. naïve; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001, vs CAT-
004. Mo-DCs monocyte-derived dendritic cells, cDCs conventional dendritic cells
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the inflamed peritoneal cavity we injected MacGreen
(Csf1R-EGFP) bone marrow monocytes [28] i.p. at day 2
into C57BL/6 wild-type (WT) recipient mice undergoing
AIP, in the presence or absence of CAM-3003 - we pre-
viously used this monocyte donor approach to demon-
strate the monocyte origin of the AIP CD115+ exudate
populations including Mo-DCs [28]. As above at day 4,
as well as at day 3, there were fewer total PECs, mono-
cytes/macrophages (R2 and R3 (MHC+/- populations
combined), Mo-DCs and cDCs if CAM-3003 was ad-
ministered (Fig. 5a). Also, the percentage of CD115+
cells that expressed Ly6C+ declined over time but this
decline was not altered by CAM-3003 (Fig. 5b). Again,
detectable GM-CSFRα surface expression on the total
CD115+ PECs was reduced by CAM-3003 (Fig. 5c).
For the total donor (GFP+) cells, fewer were retrieved
from the cavity of CAM-3003-treated mice compared to
CAT-004 isotype-treated mice (Fig. 5d). We could not
detect donor cells in the draining lymph nodes consist-
ent with there being a pro-survival effect of GM-CSF ra-
ther than an influence on cell migration (data not
shown). There were significantly fewer donor Mo-DCs
at days 3 and 4 in the CAM-3003-treated mice and a
trend towards fewer donor monocytes/macrophages (R2
and R3 populations combined) on day 3, which reached
significance on day 4 (Fig. 5e). Again the proportion of
CD115+ donor cells converting into Mo-DCs was signifi-
cantly reduced by CAM-3003 treatment (Fig. 5f ); how-
ever, the loss of surface Ly6C was not affected (Fig. 5g).
Interestingly, there appeared to be an increase over time
in detectable surface GM-CSFRα in the donor mono-
cytes (CAT-004-treated group, Fig. 5h).Therefore, following transfer of monocytes directly
into the inflamed peritoneum in the presence of CAM-
3003, the results suggest that the observed broad regula-
tion in MPS and cDC numbers and the disproportionate
impact on Mo-DCs can be driven by GM-CSF in the in-
flammatory milieu, although some additional impact on
monocyte recruitment cannot be discounted.
Transcriptome changes in donor CD115+ monocyte-
derived populations following GM-CSFRα blockade in the
AIP model
We repeated the above monocyte transfer experiment
using CD115+ CD45.1 congenic monocytes transferred
into a CD45.2 host with very similar results (data not
shown) - the donor-derived cells were then isolated and
subjected to microarray analysis so that we could exam-
ine the effect of GM-CSF on the transcriptome of this
population. Fewer genes were significantly changed com-
pared with the experimental design shown in Additional
file 3, with 889 genes changing between the transferred
monocytes and those harvested after 2 days (CD45.1+).
CAM-3003 administration affected few genes with only
three being changed compared to the CAT-004 isotype
control and an additional 20 genes relative to the PBS
control (Additional file 4). Retnla (Fizz1) and Ear1 were
decreased and Cd36 increased in CAM-3003-treated vs.
CAT-treated cells. Any KEGG pathway enrichment was
again driven by single gene changes. With this approach
in the AIP model, GM-CSF, at least at the time point ex-
amined, once more made only a minor contribution to
the gene expression changes in monocyte-derived cells
(but see “Discussion”). Decreased gene expression of
Retnla and increased gene expression of Cd36 following
Fig. 5 Granulocyte macrophage colony-stimulating factor receptor α (GM-CSFRα) blockade suppresses generation of monocyte-derived dendritic
cells (Mo-DCs) from donor monocytes in the antigen-induced peritonitis (AIP) cavity. CD115+ MacGreen bone marrow cells were adoptively
transferred intraperitoneally (i.p.) to C57BL/6 wild-type (WT) mice on day 2 following AIP induction. C57BL/6 mice were treated i.p. with
CAT-004 or CAM-3003 at the same time as the CD115+ cell transfer. Peritoneal exudate cells (PECs) were harvested on day 3 and day 4 post
AIP induction, i.e., one or two days, respectively, following CD115+ cell transfer and monoclonal antibody (mAb) treatment. a Total cells,
monocytes/macrophages (CD11c-MHCII+/-), Mo-DCs and conventional dendritic cells (cDCs) (host and donor cells). b Percentage of CD115
+CD11b+ cells that are Ly6C+ vs. Ly6C- (host and donor cells). c GM-CSFRα expression (mean fluorescence intensity (MFI)) on CD115+CD11b+ cells
(host and donor cells). d Total numbers of donor cells recovered. e Numbers of donor monocytes/macrophages (CD11c-MHCII+/-) and Mo-DCs
recovered. f Percentage of recovered donor cells that are monocytes/macrophages (CD11c-MHCII+/-) and Mo-DCs. g Percentage of recovered
donor cells that are Ly6C+ vs. Ly6C-. h GM-CSFRα expression (MFI) on recovered donor cells. Data are expressed as mean ± SEM; n = 8 mice/
group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, CAM-3003 vs. CAT-004; ##p < 0.01, CAM-3003 vs. CAT-004
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model was confirmed by quantitative PCR (data not
shown).
GM-CSFR signalling in monocytes regulates Mo-DC/
macrophage numbers in the AIP model
In order to test whether GM-CSF in the AIP peritoneumwas
acting directly via its receptor on the incoming monocytes,
Csf2rb-/-Csf2rb2-/- (CD45.2) donor monocytes (CD115+)were injected i.p. at day 2 into C57BL/6 WT (CD45.1)
mice undergoing AIP. As can be seen in Fig. 6a, at day
4 there were fewer donor monocytes/macrophages (R2
and R3 populations combined) and Mo-DCs if Csf2rb-/-
Csf2rb2-/- CD115+ bone marrow monocytes were trans-
ferred when compared to WT (CD45.2) monocyte
transfer; interestingly, the proportion of the monocytes/
macrophages and Mo-DCs recovered from the donor
monocytes did not differ between the two strains
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Mo-DCs in contrast to the data above wherein i.p.
CAM-3003 preferentially reduced the donor monocyte
to Mo-DC conversion (Fig. 5f ). It can also be noted
that the loss of Ly6C from the donor monocytes from
WT and Csf2rb-/-Csf2rb2-/- mice was similar (Fig. 6c).
The total number of CD115+ (R1–R3 populations) cells
recovered in the recipient mice was not influenced by
the strain of the monocyte donor (data not shown).
Thus, direct GM-CSF signalling appears important for
maintenance of cell number but not for the differenti-
ation of monocytes into Mo-DCs, at least when certain
markers are used (see “Discussion”).
Discussion
In the AIA model we were able to show that anti-GM-
CSF mAb, both prophylactically and therapeutically,
could ameliorate arthritis, in particular the later struc-
tural changes. These data extend our findings with GM-
CSF-/- mice [25] in this model and extend the number of
inflammation models where GM-CSF neutralization is
effective [1, 2, 35]. In contrast, neither an anti-CSF-1R
mAb nor an anti-CSF-1 mAb reduced arthritis, suggest-
ing lack of involvement of CSF-1 and IL-34, and possibly
reflecting the high neutrophil component and the rela-
tively acute nature of the model compared with other
more chronic and more macrophage-dependent arthritis
models where such blockade was effective [45–47].
We took advantage of the anti-GM-CSFRα mAb
(CAM-3003) to explore GM-CSFRα expression in the
AIA model and the effect of GM-CSFRα blockade on
synovial myeloid populations. The anti-GM-CSFRα mAb
easily detected the surface GM-CSFRα on each of the
F4/80+ MPS populations, monocytes and cDCs, but only
low levels were found on neutrophils and eosinophils.
GM-CSFRα blockade was successful at reducing the
numbers of F4/80+ MPS cells and eosinophils. ThisFig. 6 In antigen-induced peritonitis (AIP), granulocyte macrophage colony
regulates monocyte/macrophage/monocyte-derived dendritic cell (Mo-DC
monocytes from Csf2rb-/-Csf2rb2-/- or C57BL/6 wild-type (WT) mice (both
(CD45.1) mice on day 2 following AIP induction. Peritoneal exudate cells
transfer. a Numbers of donor monocytes/macrophages and Mo-DCs. b
Mo-DCs. c Percentage of donor cells that are Ly6C+ vs. Ly6C-. Data are
Csf2rb-/-Csf2rb2-/- donor cellsobservation could be clinically relevant because macro-
phage numbers in RA synovial tissue have been found to
correlate with disease activity and it has been speculated
that GM-CSF may be controlling such numbers [48].
Interestingly, among F4/80+ cells, Mo-DCs, defined here
as MHCII+CD11c+ cells, was the only population with
significantly lower numbers following anti-GM-CSFRα
mAb treatment indicating a preferential reduction. Prior
to the availability of CAM-3003 to measure surface mur-
ine GM-CSFRα directly and therefore easily, a chimeric
protein containing the Fc-fragment of human IgG1
coupled to murine GM-CSF was the method available to
measure it on myeloid populations [49].
TNF and IL-6 have been implicated in the AIA model
using mAb neutralization or gene-deficient mice, albeit
with variable degrees of efficacy [19–24]. Following
anti-TNF or anti-IL-6 mAb treatment, unlike that of
anti-GM-CSFRα mAb, we found no preferential reduc-
tion of Mo-DCs and eosinophils, but an effect on the
numbers of Gr-1+ synovial monocytes; these data sug-
gest that GM-CSF has a different mode of action in this
model than TNF and IL-6, with possible implications
for the trials targeting GM-CSF or its receptor [2]. It is
possible that higher doses of anti-TNF and anti-IL-6
mAbs may have also led to a preferential reduction of
Mo-DCs and eosinophils, although they were high
compared to those used in other murine inflammation
models [50, 51].
We also took advantage again of our convenient AIP
model to explore further, using the anti-GM-CSFRα
mAb approach, the role of GM-CSF in inflammation
[28, 32]. This model has been viewed as a relevant,
antigen-driven inflammation model to study resolution-
phase macrophages given its particularly acute nature
[52]. In both the AIA and AIP models, the relative sur-
face GM-CSFRα expression of the myeloid populations
was similar as was the preferential Mo-DC reduction-stimulating factor receptor (GM-CSFR) signalling in monocytes directly
) numbers but not Mo-DC development. CD115+ bone marrow
CD45.2) were adoptively transferred intraperitoneally (i.p.) to C57BL/6
(PECs) were harvested on day 4, i.e., two days following CD115+ cell
Percentage of donor cells that are monocytes/macrophages and
expressed as mean ± SEM; n = 5–7 mice/group; ***p < 0.001, WT vs.
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tration. GM-CSFRα blockade had a significant effect on
PEC numbers, whereas TNF and IL-6 depletion did not.
As for murine collagen-induced arthritis [11, 33, 36], the
effect on myeloid cell numbers in peritonitis upon GM-
CSFRα blockade reported above was similar to that pre-
viously observed following ligand neutralization [28].
By allowing direct injection of donor monocytes into
the inflamed site, the AIP model also enabled us to
conclude that GM-CSF signalling in the peritoneal cav-
ity itself was contributing to the increased numbers of
inflammatory Mo-DCs and monocytes/macrophages
which were shown previously to originate from infil-
trating monocytes [28]. We were also able to demon-
strate that GM-CSFR signalling in donor monocytes
themselves regulates macrophage/Mo-DC numbers;
whether this is due to a pro-survival function of GM-
CSF and/or to its ability to retain cells in the cavity is
unknown. In contrast, mixed bone marrow chimeras
lacking functional GM-CSFR in one donor population
showed that equal numbers of Mo-DCs from WT and
Csf2r-/- mice were present in the inflamed central ner-
vous system (CNS) in experimental autoimmune en-
cephalomyelitis [3]; similarly, monocytes from WT and
Csf2r-/-Csf2rb2-/- mice were able to differentiate into
Mo-DCs in equal numbers in the lungs and lung-
draining lymph nodes when adoptively transferred
intravenously into mice infected intranasally with influ-
enza virus [3].
Given the preferential depletion of Mo-DCs by both
anti-GM-CSF [28] and anti-GM-CSFRα administration
in the AIP model (Fig. 3b and c), it might have been
expected that there would have been a preferential de-
pendence for Mo-DC generation on GM-CSFR signal-
ling in the donor monocytes. However, direct GM-CSFR
signalling was not required for the differentiation of
monocytes into Mo-DCs in the AIP cavity as, despite
there being fewer recoverable CD115+ Csf2r-/-Csf2rb2-/-
donor MPS cells compared to CD115+ WT donor MPS
cells, the proportion of these donor MPS cells that had dif-
ferentiated into Mo-DCs was similar between the two
strains, noting that in this case the WT host cells are still
able to respond to GM-CSF; the reason for this result is un-
clear, although it suggests an indirect GM-CSF-dependent
mechanism, at least for the upregulation of the CD11c and
MHCII surface markers used to define Mo-DCs.
The AIP model also enabled us to demonstrate nu-
merous changes in gene expression between monocytes
and their progeny in the inflamed peritoneal cavity. Even
though the experiments above were not able to demon-
strate a dramatic GM-CSF-dependence for these tran-
scriptomic changes, it is possible that similar analyses at
earlier time points may be more fruitful [52]; however, it
could be that GM-CSF control over cell numbers may ofitself be quite an important component of GM-CSF-
dependent inflammation [27, 28, 48].
Conclusions
In summary, we show for the first time during inflamma-
tion that GM-CSFRα neutralization leads to similar
changes in myeloid populations as GM-CSF neutralization
[28], with local GM-CSF signalling in MPS cells being im-
portant for the regulation of inflammatory macrophage/
Mo-DC numbers. Our observations suggest that GM-CSF
blockade modulates inflammatory responses differently to
TNF or IL-6 blockade and may provide a greater under-
standing of how GM-CSFRα/GM-CSF inhibition is effect-
ive in RA; they may also help identify additional diseases
where targeting this pathway may provide benefit.
Additional files
Additional file 1: A Representative FACS plots showing Ly6G and Ly6C
staining of CD45+ myeloid populations in the AIA knee joint. F4/80intSSchi
eosinophils (Eos), F4/80+CD11c+MHCII+ Mo-DCs (R1), F4/80+CD11c-MHCII+
macrophages (Macs) (R2), F4/80+CD11c-MHCII- macrophages (R3), F4/80-
CD11c+ MHCII+ cDCs, F4/80-CD11b+Ly6G+ neutrophils, which are also
Ly6C+, and F4/80-CD11b+Ly6G-SScloLy6C+/- monocytes. B Representative
FACS plots of CD45+ myeloid populations in the AIA knee joint showing
Ly6G+ neutrophils are CD64- and F4/80+ macrophages/Mo-DCs are CD64+.
(PDF 235 kb)
Additional file 2: Representative FACS plots showing the gating
strategy used to identify populations in AIP. Ly6G+ neutrophils (Neutro),
CD115+CD11c+MHCII+ Mo-DCs (R1); CD115+CD11c-MHCII+ macrophages
(R2); CD115+CD11c-MHCII- monocytes (R3), CD115- Ly6G-CD11c+MHCII+
cDCs and CD115-Ly6G-CD11bintSSchi eosinophils (Eos). (DOCX 143 kb)
Additional file 3: Genes significantly changed in CD115+ cells from day
4 AIP following CAM-3003, CAT-004 or PBS treatment (day -1). CD115+
PECs were sorted from the peritoneal cavity of C57BL/6 on day 4 and
subjected to microarray analysis. Highlighted genes were increased in
CAM-3003 vs. CAT-004-treated mice; all other genes were decreased in
CAM-3003- vs. CAT-004- or PBS-treated mice. (PDF 25 kb)
Additional file 4: Genes significantly changed in CD115+ CD45.1
donor cells from day 4 AIP. C57BL/6 CD45.1 CD115+ monocytes were
transferred on day 2 into C57BL/6 CD45.2 recipient mice treated with
CAM-3003, CAT-004 or PBS following AIP induction. CD115+ CD45.1
donor cells were sorted on day 4 and subjected to microarray analysis.
Highlighted genes were increased in CAM-3003 vs. CAT-004-treated
mice; all other genes were decreased in CAM-3003- vs. CAT-004- or
PBS-treated mice. (PDF 15 kb)
Additional file 5: Array data supporting Additional file 3. Data shown as
normalised intensities. (XLSX 13054 kb)
Additional file 6: Array data supporting Additional file 4. Data shown as
normalised intensities. (XLSX 11003 kb)
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